Search results for "PHASES"

showing 10 items of 282 documents

TITAFORM - Precision Hot Forming, development of innovative hot-forming processes of aeronautical components in Ti-alloy with low buy/fly ratio: an I…

2012

In the paper the description of the project TITAFORM is provided. The project has been financed on the call "PON Linea 1" of the Italian government and represents an effective example of cooperation between academy and industry. The project is focused on the beta forging and hot stretch forming operations of titanium alloys. �� 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Aeronautical components Beta forging Hot forming Magnesium alloy sheets Stretch-forming Ti alloyForging Titianium Phases transformationMetal formingMagnesium alloys Titanium alloys Upsetting (forming)Settore ING-IND/16 - Tecnologie E Sistemi Di Lavorazione
researchProduct

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

2012

Abstract Abstract 1632 Background: OFA is a fully human monoclonal antibody that binds to both the large and small extracellular loops of CD20. OFA is currently approved for patients (pts) with refractory chronic lymphocytic leukemia and has demonstrated activity in non-Hodgkin's lymphomas, including follicular lymphoma (FL). We previously reported results of a phase II study of OFA in combination with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg daily for 5 days) chemotherapy (O-CHOP) in pts with previously untreated FL (Czuczman et al. Br J Haematol. 2012;157:438). We now report updated efficacy, safety and pharmacokinetic (PK) follow-up…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaPhases of clinical researchCHOPOfatumumabBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPrednisoneInternal medicinemedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthSurgerychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multice…

2020

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but…

Oncologymedicine.medical_specialtyEsophageal NeoplasmsPaclitaxel[SDV]Life Sciences [q-bio]medicine.medical_treatmentEsophageal cancerPhases of clinical researchIrinotecan03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyCisplatin0303 health sciencesChemotherapyHepatologyPerformance statusbusiness.industryGastroenterologyEsophageal cancermedicine.disease3. Good healthSurvival RateIrinotecanPaclitaxelchemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionQuality of LifeSquamous cell cancerEsophageal Squamous Cell CarcinomaFluorouracilFranceNeoplasm Recurrence Localbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Theoretical and Empirical Description of Phases in the Proving Processes of Undergraduates

2018

International audience; In the presented study we adopt a process-oriented perspective on proving in order to gain further insights into relevant actions and typical obstacles in undergraduates' approaches to proving. The primary aim is to theoretically and empirically describe different phases, understood as bunches of intentionally closely related actions of proving. Therefore, we suggest a theoretical model of the proving process and confirm empirically that it can be used as an analytical tool for proving approaches. Based on this model, several proving processes have been analysed. In this paper we present first findings regarding the contribution of each phase to proof construction as…

proving process[SHS.EDU]Humanities and Social Sciences/Education[MATH.MATH-HO]Mathematics [math]/History and Overview [math.HO][SHS.EDU] Humanities and Social Sciences/Education[MATH.MATH-HO] Mathematics [math]/History and Overview [math.HO]proving cycle THEORETICAL BACKGROUNDproof constructionphasesproving cycle
researchProduct

On critical properties of the Berry curvature in the Kitaev honeycomb model

2019

We analyse the Kitaev honeycomb model, by means of the Berry curvature with respect to Hamiltonian parameters. We concentrate on the ground-state vortex-free sector, which allows us to exploit an appropriate Fermionisation technique. The parameter space includes a time-reversal breaking term which provides an analytical headway to study the curvature in phases in which it would otherwise vanish. The curvature is then analysed in the limit in which the time-reversal-symmetry-breaking perturbation vanishes. This provides remarkable information about the topological phase transitions of the model. The Berry curvature in itself exhibits no singularities at criticality, nevertheless it distingui…

Statistics and ProbabilityQuantum phase transitionPhysicsCondensed matter physicsHoneycomb (geometry)Statistical and Nonlinear PhysicsBerry connection and curvatureStatistics Probability and UncertaintyTopological phases of Matter geometric phase phase transition anyons and fractional statistical models quantum phase transitionsJournal of Statistical Mechanics: Theory and Experiment
researchProduct

Online gambling: A treatment for sports betting addiction

2020

Resumen Antecedentes : el juego de azar online (apuestas, juegos de casino, póquer, etc.) es una actividad que se está extendiendo mundialmente, incluso en los países en los cuales todavía no está legalizado. A pesar de que la situación en Latinoamérica es de lo más diversa, es probable que conforme se desarrolle y promocione el juego online aparezcan problemas de adicción, de forma similar a lo que está ocurriendo en España desde que este tipo de juegos se legalizó en 2011. De manera que la ciencia psicológica debe ir desarrollando programas de tratamiento que hagan frente a la nueva realidad. Objetivo: el artículo presenta el procedimiento seguido para el tratamiento de un joven con probl…

medicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectOnline gamblingtrastorno por juego de apuestasPromotion (rank)tratamientojuego ético.online gamblingIntervention (counseling)medicinePsychologyPsychiatryjuventudmedia_commonLegalizationyouthtreatmentAddictionTreatment phasesjuego onlinegambling disorderjuego éticoBF1-990Cognitive behavioral therapyethical gambling.Test scoreadicción al juegoPsychologygambling addiction
researchProduct

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

2020

Contains fulltext : 229341.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Numerous pharmacological compounds that target the different molecular targets involved in the pathobiology of nonalcoholic steatohepatitis (NASH) are currently in clinical testing. So far, there are no regulatory approvals. AREAS COVERED: This paper sheds light on the molecular pathways involved in NASH and the drugs targeting these pathways. We have identified 10 compounds whose clinical development program has been halted. Moreover, we explore early phase clinical trials and dissect the reasons for termination of development. EXPERT OPINION: The main goal of NASH pharmacotherapy is to halt or reverse hepati…

Liver Cirrhosis0301 basic medicineNonalcoholic steatohepatitisAnti-Inflammatory AgentsPhases of clinical researchBioinformaticsdigestive system03 medical and health sciences0302 clinical medicineDrug DevelopmentNon-alcoholic Fatty Liver DiseasemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPharmacologybusiness.industryFatty liverGeneral Medicinemedicine.diseasedigestive system diseasesRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyDrug development030220 oncology & carcinogenesisMolecular targetsbusinessExpert Opinion on Investigational Drugs
researchProduct

Estudio experimental comparado de marcadores bioquímicos en la infección por Fasciola hepatica y F. gigantica

2017

Fascioliasis is caused by the genetically and phenotypically very close Fasciola hepatica and F. gigantica. The latter, always considered secondary in human infection, appears nowadays increasingly involved in human endemic areas of Africa and Asia. Unfortunately, little is known about the pathogenicity of this liver fluke species, mainly due to difficulties assessing the moment of a patient's infection in the anamnesis and in the differential diagnosis with F. hepatica. This is the first experimental study comparing F. hepatica and F. gigantica in a long-term study of up to 24 weeks with genotypically and phenotypically standardised fluke strains in the same animal model host, the Guirra s…

morbidity indicatorsIgGparasitic diseasesphysiopathogenecityegg sheddingfasciola hepaticacoproantigenbiochemical parametershuman disease extrapolationsheep experimental infectionfasciola giganticaacute and chronic phases
researchProduct

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquam…

2013

Abstract Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). Patients and methods In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500mg/m 2 ) and cisplatin (75mg/m 2 ) on Day 1 (21-day cycles) plus weekly cetuximab (400mg/m 2 loading dose, then 250mg/m 2 ) for 4–6 cycles. Non-progressing patients received maintenance therapy consisting of pemetrexed and cetuximab as above until disease progression. All patients received vitamin supplementation, dexameth…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyGuanineLung NeoplasmsPhases of clinical researchCetuximabPemetrexedAntibodies Monoclonal HumanizedLoading doseMaintenance ChemotherapyTranslational Research BiomedicalMaintenance therapyGlutamatesInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansLung cancerSurvival rateAgedNeoplasm StagingCetuximabbusiness.industryInduction ChemotherapyMiddle Agedmedicine.diseasePemetrexedTreatment OutcomeOncologyFemaleCisplatinbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPleural effusionmedicine.drug_classnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaVinorelbineVinblastineGastroenterologyAntimetaboliteDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyInjections IntravenousFemalebusinessmedicine.drug
researchProduct